Florian M Marx1, Ted Cohen2, Nicolas A Menzies3, Joshua A Salomon4, Grant Theron5, Reza Yaesoubi6. 1. DSI-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa; Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. Electronic address: fmarx@sun.ac.za. 2. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA. 3. Department of Global Health and Population, Harvard T H Chan School of Public Health, Boston, MA, USA. 4. Department of Medicine, Stanford University, Palo Alto, CA, USA. 5. DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; South African Medical Research Council Centre for Tuberculosis Research, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. 6. Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA.
Abstract
BACKGROUND: In settings of high tuberculosis incidence, previously treated individuals remain at high risk of recurrent tuberculosis and contribute substantially to overall disease burden. Whether tuberculosis case finding and preventive interventions among previously treated people are cost-effective has not been established. We aimed to estimate costs and health benefits of annual post-treatment follow-up examinations and secondary preventive therapy for tuberculosis in a tuberculosis-endemic setting. METHODS: We developed a transmission-dynamic mathematical model and calibrated it to data from two high-incidence communities of approximately 40 000 people in suburban Cape Town, South Africa. We used the model to estimate overall cost and disability-adjusted life-years (DALYs) associated with annual follow-up examinations and secondary isoniazid preventive therapy (IPT), alone and in combination, among individuals completing tuberculosis treatment. We investigated scenarios under which these interventions were restricted to the first year after treatment completion, or extended indefinitely. For each intervention scenario, we projected health system costs and DALYs averted with respect to the current status quo of tuberculosis control. All estimates represent mean values derived from 1000 epidemic trajectories simulated over a 10-year period (2019-28), with 95% uncertainty intervals (UIs) calculated as the 2·5th and 97·5th percentile values. FINDINGS: We estimated that a single follow-up examination at the end of the first year after treatment completion combined with 12 months of secondary IPT would avert 2472 DALYs (95% UI -888 to 7801) over a 10-year period and is expected to be cost-saving compared with current control efforts. Sustained annual follow-up and continuous secondary IPT beyond the first year after treatment would avert an additional 1179 DALYs (-1769 to 4377) over 10 years at an expected additional cost of US$18·2 per DALY averted. Strategies of follow-up without secondary IPT were dominated (ie, expected to result in lower health impact at higher costs) by strategies that included secondary IPT. INTERPRETATION: In this high-incidence setting, post-treatment follow-up and secondary preventive therapy can accelerate declines in tuberculosis incidence and potentially save resources for tuberculosis control. Empirical trials to assess the feasibility of these interventions in settings most severely affected by tuberculosis are needed. FUNDING: National Institutes of Health, Günther Labes Foundation, Oskar Helene Heim Foundation.
BACKGROUND: In settings of high tuberculosis incidence, previously treated individuals remain at high risk of recurrent tuberculosis and contribute substantially to overall disease burden. Whether tuberculosis case finding and preventive interventions among previously treated people are cost-effective has not been established. We aimed to estimate costs and health benefits of annual post-treatment follow-up examinations and secondary preventive therapy for tuberculosis in a tuberculosis-endemic setting. METHODS: We developed a transmission-dynamic mathematical model and calibrated it to data from two high-incidence communities of approximately 40 000 people in suburban Cape Town, South Africa. We used the model to estimate overall cost and disability-adjusted life-years (DALYs) associated with annual follow-up examinations and secondary isoniazid preventive therapy (IPT), alone and in combination, among individuals completing tuberculosis treatment. We investigated scenarios under which these interventions were restricted to the first year after treatment completion, or extended indefinitely. For each intervention scenario, we projected health system costs and DALYs averted with respect to the current status quo of tuberculosis control. All estimates represent mean values derived from 1000 epidemic trajectories simulated over a 10-year period (2019-28), with 95% uncertainty intervals (UIs) calculated as the 2·5th and 97·5th percentile values. FINDINGS: We estimated that a single follow-up examination at the end of the first year after treatment completion combined with 12 months of secondary IPT would avert 2472 DALYs (95% UI -888 to 7801) over a 10-year period and is expected to be cost-saving compared with current control efforts. Sustained annual follow-up and continuous secondary IPT beyond the first year after treatment would avert an additional 1179 DALYs (-1769 to 4377) over 10 years at an expected additional cost of US$18·2 per DALY averted. Strategies of follow-up without secondary IPT were dominated (ie, expected to result in lower health impact at higher costs) by strategies that included secondary IPT. INTERPRETATION: In this high-incidence setting, post-treatment follow-up and secondary preventive therapy can accelerate declines in tuberculosis incidence and potentially save resources for tuberculosis control. Empirical trials to assess the feasibility of these interventions in settings most severely affected by tuberculosis are needed. FUNDING: National Institutes of Health, Günther Labes Foundation, Oskar Helene Heim Foundation.
Authors: Jussi J Saukkonen; David L Cohn; Robert M Jasmer; Steven Schenker; John A Jereb; Charles M Nolan; Charles A Peloquin; Fred M Gordin; David Nunes; Dorothy B Strader; John Bernardo; Raman Venkataramanan; Timothy R Sterling Journal: Am J Respir Crit Care Med Date: 2006-10-15 Impact factor: 21.405
Authors: Hridesh Mishra; Byron W P Reeve; Zaida Palmer; Judy Caldwell; Tania Dolby; Charissa C Naidoo; Jennifer G Jackson; Samuel G Schumacher; Claudia M Denkinger; Andreas H Diacon; Paul D van Helden; Florian M Marx; Robin M Warren; Grant Theron Journal: Lancet Respir Med Date: 2020-02-14 Impact factor: 30.700
Authors: Gavin J Churchyard; Katherine Fielding; Salome Charalambous; John H Day; Elizabeth L Corbett; Richard J Hayes; Richard E Chaisson; Kevin M De Cock; Badara Samb; Alison D Grant Journal: AIDS Date: 2003-09-26 Impact factor: 4.177
Authors: Helen Ayles; Monde Muyoyeta; Elizabeth Du Toit; Ab Schaap; Sian Floyd; Musonda Simwinga; Kwame Shanaube; Nathaniel Chishinga; Virginia Bond; Rory Dunbar; Petra De Haas; Anelet James; Nico C Gey van Pittius; Mareli Claassens; Katherine Fielding; Justin Fenty; Charalampos Sismanidis; Richard J Hayes; Nulda Beyers; Peter Godfrey-Faussett Journal: Lancet Date: 2013-08-01 Impact factor: 79.321
Authors: Saskia den Boon; Schalk W P van Lill; Martien W Borgdorff; Donald A Enarson; Suzanne Verver; Eric D Bateman; Elvis Irusen; Carl J Lombard; Neil W White; Christine de Villiers; Nulda Beyers Journal: Emerg Infect Dis Date: 2007-08 Impact factor: 6.883